tradingkey.logo

Amphastar Pharmaceuticals Inc

AMPH
27.120USD
+0.310+1.16%
Fechamento 12/26, 16:00ETCotações atrasadas em 15 min
1.26BValor de mercado
11.50P/L TTM

Amphastar Pharmaceuticals Inc

27.120
+0.310+1.16%

Mais detalhes de Amphastar Pharmaceuticals Inc Empresa

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.

Informações de Amphastar Pharmaceuticals Inc

Código da empresaAMPH
Nome da EmpresaAmphastar Pharmaceuticals Inc
Data de listagemJun 25, 2014
CEOZhang (Yongfeng Yongfeng)
Número de funcionários2028
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 25
Endereço11570 6th St
CidadeRANCHO CUCAMONGA
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal91730
Telefone19099809484
Sitehttps://amphastar.com/
Código da empresaAMPH
Data de listagemJun 25, 2014
CEOZhang (Yongfeng Yongfeng)

Executivos da empresa Amphastar Pharmaceuticals Inc

Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Rong Zhou
Mr. Rong Zhou
Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
197.10K
+5.69%
Dr. Howard S. Lee, Ph.D.
Dr. Howard S. Lee, Ph.D.
Independent Director
Independent Director
148.90K
+2.90%
Mr. Floyd F. Petersen
Mr. Floyd F. Petersen
Independent Director
Independent Director
72.45K
-0.69%
Mr. William J. Peters
Mr. William J. Peters
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director
55.44K
-0.49%
Mr. Richard K. Prins
Mr. Richard K. Prins
Lead Independent Director
Lead Independent Director
32.11K
--
Ms. Gayle Deflin
Ms. Gayle Deflin
Independent Director
Independent Director
7.84K
+188.59%
Mr. Jacob Liawatidewi
Mr. Jacob Liawatidewi
Executive Vice President of Sales and Marketing, Corporate Administration Center, President of Amphastar France Pharmaceuticals, S.A.S, Company Secretary, Director
Executive Vice President of Sales and Marketing, Corporate Administration Center, President of Amphastar France Pharmaceuticals, S.A.S, Company Secretary, Director
--
--
Mr. Dan Dischner
Mr. Dan Dischner
Vice President - Corporate Communications
Vice President - Corporate Communications
--
--
Ms. Diane G. Gerst
Ms. Diane G. Gerst
Independent Director
Independent Director
--
--
Mr. David Gaugh
Mr. David Gaugh
Director
Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Rong Zhou
Mr. Rong Zhou
Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
197.10K
+5.69%
Dr. Howard S. Lee, Ph.D.
Dr. Howard S. Lee, Ph.D.
Independent Director
Independent Director
148.90K
+2.90%
Mr. Floyd F. Petersen
Mr. Floyd F. Petersen
Independent Director
Independent Director
72.45K
-0.69%
Mr. William J. Peters
Mr. William J. Peters
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director
55.44K
-0.49%
Mr. Richard K. Prins
Mr. Richard K. Prins
Lead Independent Director
Lead Independent Director
32.11K
--
Ms. Gayle Deflin
Ms. Gayle Deflin
Independent Director
Independent Director
7.84K
+188.59%

Detalhamento da receita

Moeda: USDAtualizado em: seg, 6 de out
Moeda: USDAtualizado em: seg, 6 de out
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Os dados relevantes ainda não foram divulgados pela empresa.
Por RegiãoUSD
Nome
Receita
Proporção
United States
167.00M
95.75%
France
7.11M
4.08%
China
299.00K
0.17%
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.

Distribuição de ações

Atualizado em: dom, 16 de nov
Atualizado em: dom, 16 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Applied Physics & Chemistry Laboratories, Inc.
14.86%
BlackRock Institutional Trust Company, N.A.
10.75%
Zhang (Jack Yongfeng)
5.71%
The Vanguard Group, Inc.
5.68%
TD Asset Management Inc.
4.20%
Outro
58.80%
Investidores
Investidores
Proporção
Applied Physics & Chemistry Laboratories, Inc.
14.86%
BlackRock Institutional Trust Company, N.A.
10.75%
Zhang (Jack Yongfeng)
5.71%
The Vanguard Group, Inc.
5.68%
TD Asset Management Inc.
4.20%
Outro
58.80%
Tipos de investidores
Investidores
Proporção
Investment Advisor
40.55%
Investment Advisor/Hedge Fund
22.63%
Corporation
14.86%
Individual Investor
9.43%
Hedge Fund
6.47%
Research Firm
2.82%
Pension Fund
1.06%
Bank and Trust
0.34%
Sovereign Wealth Fund
0.12%
Outro
1.72%

Participação acionária institucional

Atualizado em: seg, 8 de dez
Atualizado em: seg, 8 de dez
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
586
33.97M
85.20%
+16.67K
2025Q3
603
33.96M
84.80%
+202.84K
2025Q2
607
33.74M
83.87%
-544.61K
2025Q1
597
34.53M
80.40%
-3.80M
2024Q4
593
35.69M
79.40%
-112.11K
2024Q3
575
35.68M
75.48%
+965.70K
2024Q2
565
34.64M
73.86%
+833.26K
2024Q1
548
33.97M
73.49%
-1.92M
2023Q4
531
33.91M
72.12%
+1.03M
2023Q3
499
32.97M
71.03%
+509.94K
Ver Mais

Atividade dos acionistas

Nome
Ações detidas
Proporção
Variação
Var. %
Data
Applied Physics & Chemistry Laboratories, Inc.
6.83M
14.68%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.12M
11.02%
-399.35K
-7.23%
Jun 30, 2025
Zhang (Jack Yongfeng)
2.62M
5.64%
+200.00K
+8.25%
Jun 13, 2025
The Vanguard Group, Inc.
2.67M
5.73%
+251.01K
+10.40%
Jun 30, 2025
TD Asset Management Inc.
2.03M
4.38%
-177.21K
-8.01%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
1.63M
3.5%
+270.52K
+19.94%
Jun 30, 2025
State Street Investment Management (US)
1.58M
3.39%
-28.38K
-1.77%
Jun 30, 2025
Fuller & Thaler Asset Management Inc.
1.26M
2.72%
+174.00
+0.01%
Jun 30, 2025
Boston Trust Walden Company
1.18M
2.53%
-39.17K
-3.22%
Jun 30, 2025
Epoch Investment Partners, Inc.
1.24M
2.67%
-19.94K
-1.58%
Jun 30, 2025
Ver Mais

ETFs Relacionados

Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Invesco Pharmaceuticals ETF
2.25%
State Street SPDR S&P Pharmaceuticals ETF
1.47%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.38%
Invesco S&P SmallCap 600 GARP ETF
1.12%
Acquirers Small and Micro Deep Value ETF
0.87%
Pacer US Small Cap Cash Cows Growth Leaders ETF
0.77%
Invesco S&P SmallCap Health Care ETF
0.56%
First Trust Small Cap Value AlphaDEX Fund
0.5%
Distillate Small/Mid Cash Flow ETF
0.45%
VictoryShares Small Cap Free Cash Flow ETF
0.37%
Ver Mais
Invesco Pharmaceuticals ETF
Proporção2.25%
State Street SPDR S&P Pharmaceuticals ETF
Proporção1.47%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporção1.38%
Invesco S&P SmallCap 600 GARP ETF
Proporção1.12%
Acquirers Small and Micro Deep Value ETF
Proporção0.87%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Proporção0.77%
Invesco S&P SmallCap Health Care ETF
Proporção0.56%
First Trust Small Cap Value AlphaDEX Fund
Proporção0.5%
Distillate Small/Mid Cash Flow ETF
Proporção0.45%
VictoryShares Small Cap Free Cash Flow ETF
Proporção0.37%

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados

Desdobramento de ações

Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados

Perguntas frequentes

Quem são os cinco principais acionistas de Amphastar Pharmaceuticals Inc?

Os cinco principais acionistas de Amphastar Pharmaceuticals Inc são:
Applied Physics & Chemistry Laboratories, Inc. detém 6.83M Ações, representando 14.68% do total de Ações.
BlackRock Institutional Trust Company, N.A. detém 5.12M Ações, representando 11.02% do total de Ações.
Zhang (Jack Yongfeng) detém 2.62M Ações, representando 5.64% do total de Ações.
The Vanguard Group, Inc. detém 2.67M Ações, representando 5.73% do total de Ações.
TD Asset Management Inc. detém 2.03M Ações, representando 4.38% do total de Ações.

Quais são os três principais tipos de acionistas de Amphastar Pharmaceuticals Inc?

Os três principais tipos de acionistas da Amphastar Pharmaceuticals Inc são:
Applied Physics & Chemistry Laboratories, Inc.
BlackRock Institutional Trust Company, N.A.
Zhang (Jack Yongfeng)

Quantas instituições possuem ações da Amphastar Pharmaceuticals Inc (AMPH)?

Em 2025Q4, 586 instituições possuíam ações da Amphastar Pharmaceuticals Inc, com valor de mercado aproximado de 33.97M, representando 85.20% do total de ações. Em comparação com 2025Q3, a participação institucional aumentou em 0.40%.

Qual é a maior fonte de receita da Amphastar Pharmaceuticals Inc?

Em FY2025Q2, o segmento de negócios -- gerou a maior receita para Amphastar Pharmaceuticals Inc, totalizando -- e representando --% da receita total.
KeyAI